Bezpieczeństwo stosowania hormonalnej terapii menopauzalnej Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2019
Słowa kluczowe:
hormonalna terapia zastępcza, menopauza, ryzyko sercowo-naczyniowe, nowotwory, estrogen, progesteron
##plugins.themes.bootstrap3.article.main##
Abstrakt
Hormonalna terapia menopauzalna jest stosowana w celu likwidacji uciążliwych objawów wynikających z naturalnych zmian gospodarki hormonalnej związanych z wiekiem. Dodatkowo może zmniejszać ryzyko sercowo-naczyniowe oraz ryzyko zachorowania na raka szyjki macicy. Dobór odpowiedniego preparatu, dawki i formy podania pozwala zredukować ryzyko wystąpienia działań niepożądanych.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Skrzypulec-Plinta, V., Jagiełło-Gruszfeld, A., Śliż , D., & Mamcarz , A. (2019). Bezpieczeństwo stosowania hormonalnej terapii menopauzalnej. Medycyna Faktów , 12(2(43), 120-124. https://doi.org/10.24292/01.MF.0219.6
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Temkin S.M., Mallen A., Bellavance E. et al.: The role of menopausal hormone therapy in women with or at risk of ovarian and breast cancers: Misconceptions and current directions. Cancer 2018. DOI: 10.1002/cncr.31911. [Epub ahead of print].
2. Chan L.Y., Yuen P.M.: Influence of the Women’s Health Initiative trial on the practice of prophylactic oophorectomy and the prescription of estrogen therapy. Fertil. Steril. 2004; 81: 1699-1700.
3. Lupo M., Dains J.E., Madsen L.T.: Hormone replacement therapy: an increased risk of recurrence and mortality for breast cancer patients? J. Adv. Pract. Oncol. 2015; 6(4): 322-330.
4. Palacios S, Mejia A. Progestogen safety and tolerance in hormonal replacement therapy. Expert Opin. Drug Saf. 2016; 15: 1515-1525.
5. Kotsopoulos J., Gronwald J., Karlan B.Y. et al.: Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers. JAMA Oncol. 2018; 4: 1059-1065.
6. Marchetti C., De Felice F., Boccia S. et al.: Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis. Crit. Rev. Oncol. Hematol. 2018 132:111-115. doi: 10.1016/j.critrevonc.2018.09.018.
7. Angiolia R., Luveroa D., Armentob G. et al.: Hormone replacement therapy in cancer survivors: Utopia? Crit. Rev. Oncol. Hematol. 2018; 124: 51-60.
8. Kuhle C.L., Kapoor E., Richa Sood R. et al.: Menopausal hormone therapy in cancer survivors: A narrative review of the literature. Maturitas 2016; 92: 86-96.
9. Fahlen M., Fornander T., Johansson H. et al.: Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur. J. Cancer 2013; 49: 52-59.
10. Whicker M., Black J., Altwerger G. et al.: Management of sexuality, intimacy, and menopause symptoms in patients with ovarian cancer. Am. J. Obstet. Gynecol. 2017: 395-403.
11. Stampfer M., Colditz G.: Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Preventive Medicine 1991; 20: 47‐63.
12. Psaty B.M., Heckbert S.R., Atkins D. et al.: The risk of myocardial infarction associated with the combined use of estrogen and progestins in postmenopausal women. Arch. Intern. Med. 1994; 154(12): 1333‐1339.
13. Hulley S., Grady D., Bush T. et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280(7): 605‐613.
14. Grady D., Wenger N., Herrington D. et al.: Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Ann. Intern. Med. 2000; 132: 689‐696.
15. Rossouw J., Anderson G., Prentice R. et al.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women’s health initiative randomized controlled trial. JAMA 2002; 288(3): 321‐333.
16. Cushman M., Kuller L.H., Prentice R. et al.: Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292(13): 1573‐1580.
17. Rossouw J.E., Prentice R.L., Manson J.E. et al.: Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297(13): 1465-1477.
18. Schierbeck L.L., Rejnmark L., Tofteng C.L. et al.: Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012; 345: e6409.
19. Boardman H.M.P., Hartley L., Eisinga A. et al.: Hormone therapy for preventing cardiovascular disease in post‐menopausal women. Cochrane Database of Systematic Reviews 2015; Issue 3. Art. No.: CD002229. DOI: 10.1002/14651858.CD002229.pub4.
20. Dębski R.: Endokrynologia ginekologiczna. PZWL, Warszawa 2018.
21. Zborowska K., Skrzypulec-Plinta V., Sarnik A.: Bezpieczeństwo stosowania terapii hormonalnej wieku menopauzalnego. Forum Położnictwa i Ginekologii 2018; 42/464442: 57-64.
22. Rekomendacje Polskiego Towarzystwa Ginekologicznego 2006–2011. Progestageny w hormonalnej terapii zastępczej. Ginekologia Polska 2006; 77: 743-745.
23. Rekomendacje Polskiego Towarzystwa Menopauzy i Andropauzy na temat hormonalnej terapii menopauzy. Przegląd Menopauzalny 2014; 18(1): 1-8.
24. The 2017 Hormone therapy position statement of The North American Menopause Society. The NAMS2017 Hormone Therapy Position Statement Advisory Panel. Menopause 2017; 24(7): 728-753.
25. Fournier A., Fabre A., Mesrine S. et al.: Use of different postmenopausal hormone therapies and risk of histology-and hormone receptor-defined invasive breast cancer. J. Clin. Oncol. 2008; 26: 1260-1268.
2. Chan L.Y., Yuen P.M.: Influence of the Women’s Health Initiative trial on the practice of prophylactic oophorectomy and the prescription of estrogen therapy. Fertil. Steril. 2004; 81: 1699-1700.
3. Lupo M., Dains J.E., Madsen L.T.: Hormone replacement therapy: an increased risk of recurrence and mortality for breast cancer patients? J. Adv. Pract. Oncol. 2015; 6(4): 322-330.
4. Palacios S, Mejia A. Progestogen safety and tolerance in hormonal replacement therapy. Expert Opin. Drug Saf. 2016; 15: 1515-1525.
5. Kotsopoulos J., Gronwald J., Karlan B.Y. et al.: Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers. JAMA Oncol. 2018; 4: 1059-1065.
6. Marchetti C., De Felice F., Boccia S. et al.: Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis. Crit. Rev. Oncol. Hematol. 2018 132:111-115. doi: 10.1016/j.critrevonc.2018.09.018.
7. Angiolia R., Luveroa D., Armentob G. et al.: Hormone replacement therapy in cancer survivors: Utopia? Crit. Rev. Oncol. Hematol. 2018; 124: 51-60.
8. Kuhle C.L., Kapoor E., Richa Sood R. et al.: Menopausal hormone therapy in cancer survivors: A narrative review of the literature. Maturitas 2016; 92: 86-96.
9. Fahlen M., Fornander T., Johansson H. et al.: Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur. J. Cancer 2013; 49: 52-59.
10. Whicker M., Black J., Altwerger G. et al.: Management of sexuality, intimacy, and menopause symptoms in patients with ovarian cancer. Am. J. Obstet. Gynecol. 2017: 395-403.
11. Stampfer M., Colditz G.: Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Preventive Medicine 1991; 20: 47‐63.
12. Psaty B.M., Heckbert S.R., Atkins D. et al.: The risk of myocardial infarction associated with the combined use of estrogen and progestins in postmenopausal women. Arch. Intern. Med. 1994; 154(12): 1333‐1339.
13. Hulley S., Grady D., Bush T. et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280(7): 605‐613.
14. Grady D., Wenger N., Herrington D. et al.: Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Ann. Intern. Med. 2000; 132: 689‐696.
15. Rossouw J., Anderson G., Prentice R. et al.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women’s health initiative randomized controlled trial. JAMA 2002; 288(3): 321‐333.
16. Cushman M., Kuller L.H., Prentice R. et al.: Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292(13): 1573‐1580.
17. Rossouw J.E., Prentice R.L., Manson J.E. et al.: Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297(13): 1465-1477.
18. Schierbeck L.L., Rejnmark L., Tofteng C.L. et al.: Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012; 345: e6409.
19. Boardman H.M.P., Hartley L., Eisinga A. et al.: Hormone therapy for preventing cardiovascular disease in post‐menopausal women. Cochrane Database of Systematic Reviews 2015; Issue 3. Art. No.: CD002229. DOI: 10.1002/14651858.CD002229.pub4.
20. Dębski R.: Endokrynologia ginekologiczna. PZWL, Warszawa 2018.
21. Zborowska K., Skrzypulec-Plinta V., Sarnik A.: Bezpieczeństwo stosowania terapii hormonalnej wieku menopauzalnego. Forum Położnictwa i Ginekologii 2018; 42/464442: 57-64.
22. Rekomendacje Polskiego Towarzystwa Ginekologicznego 2006–2011. Progestageny w hormonalnej terapii zastępczej. Ginekologia Polska 2006; 77: 743-745.
23. Rekomendacje Polskiego Towarzystwa Menopauzy i Andropauzy na temat hormonalnej terapii menopauzy. Przegląd Menopauzalny 2014; 18(1): 1-8.
24. The 2017 Hormone therapy position statement of The North American Menopause Society. The NAMS2017 Hormone Therapy Position Statement Advisory Panel. Menopause 2017; 24(7): 728-753.
25. Fournier A., Fabre A., Mesrine S. et al.: Use of different postmenopausal hormone therapies and risk of histology-and hormone receptor-defined invasive breast cancer. J. Clin. Oncol. 2008; 26: 1260-1268.